Coronado's worm therapy fails in Crohn's trial, stock drops 67%
This article was originally published in Scrip
Shares of Coronado Biosciences lost almost two-thirds of their value on news that the company’s worm therapy failed in a study treating patients with the inflammatory bowel disease Crohn’s.
You may also be interested in...
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.
Biogen Idec CEO George Scangos is frank about his ambitions to dominate the market for hemophilia therapies, an opportunity he compares to the big biotech’s lead treating multiple sclerosis.